Based in Melbourne, Cipla Australia has a vast pipeline of products that are supplied in Australia as well as US & EU. Millions of Australians have access to a Cipla manufactured product through our community pharmacy partners around Australia. Our state-of-the-art manufacturing facilities are TGA approved as well as being USFDA (USA) and MHRA (UK) approved. Cipla Australia has over 200 registered formulations with TGA through partnerships with market leaders and on its own. The list of registered medicines includes OTC (Over the Counter), Prescription and hospital medicines. We are also involved in helping Australians access medicines through the SAS (Special Access Scheme). Cipla has earned a name for maintaining world-class quality across all our manufacturing units, products and services. Globally, we have been granted about 100 patents. Patent filing includes drug substances, drug products, platform technologies, IP on polymorphs and crystallinity, and medical devices.
Cipla has a long heritage of being a world leader in Respiratory Therapy. We pride ourselves in having the world’s largest respiratory range of drugs, dosage forms and devices for COPD and Asthma. Our products are available in more than 100 countries worldwide. Key products were successfully launched in many European countries e.g. UK, Germany, Belgium, Netherlands, Czech Republic and Croatia. Cipla Australia’s respiratory portfolio products can be accessed here.